Program
2,4-thiazolidinedione
Also written as “Thiazolidinedione” and “Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione”.
Its studies are mostly in Diabetes Mellitus · Diabetes Mellitus, Type 2, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eurofarma Laboratorios | 10 open or running | phase 3since Jun 30, 2025 | Jun 30, 2025 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 3since Jan 24, 2013 | Jan 24, 2013 | none ahead |
| Sanofi | 10 open or running | phase 3since Sep 30, 2002 | Sep 30, 2002 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 30, 2002First study: phase 3 study in Diabetes MellitusNew to SanofiSanofi · NCT00046462 · 240 enrolled · United States
- Jan 24, 2013GlaxoSmithKline’s first study: phase 3 study in Diabetes MellitusNew to GlaxoSmithKlineGlaxoSmithKline · NCT01777282 · 374 enrolled · Japan
- Jun 30, 2025Eurofarma Laboratorios’ first study: phase 3 study in Diabetes Mellitus, Type 2New to Eurofarma LaboratoriosEurofarma Laboratorios · NCT07057479 · Brazil
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07057479Diabetes Mellitus, Type 2 · Brazil | 3 | Withdrawn | Eurofarma Laboratorios | Feb 2028 | 0 |
| NCT01777282Diabetes Mellitus · Japan | 3 | Completed | GlaxoSmithKline | Jan 27, 2015 | 374 |
| NCT00046462Diabetes Mellitus · United States | 3 | Completed | Sanofi | Nov 2004 | 240 |
How it is read
Names in the registry
- “Thiazolidinedione”, 2 entries
- “Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, 2 studies
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.